USC Norris Comprehensive Cancer Center - Keck School of Medicine
University of Southern California
Los Angeles, CA
Accepting patients
TRIlogy-4
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti CD38 Antibody
- T Cell Engager (TCE)
- Trispecific Antibody
- BCMA
- CD3
- GPRC5D
- Randomization
- Phase 3
Accepting patients
Surzetoclax (ABBV-453)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) Given as Monotherapy or in Combination With Antimyeloma Regimens in Subjects With Multiple Myeloma
- BCL-2 Inhibitor
- Phase 1/2
Accepting patients
QXL138AM
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
- Masked Immunocytokine (MIC)
- CD138
- Phase 1
1 hidden based on your filters.Show All